ICON provides strategy and management in support of non-clinical drug development for all Phases.
What is Early Precision QT – and why is this important to you?
Leveraging iCardiac’s Early Precision QT analysis, ICON offers a cost-effective alternative to Thorough QT (TQT) studies. Combining its High Precision QT analysis method and Exposure Response (ER) modeling, this approach empowers accelerated cardiac safety analysis in First in Man studies.
Take advantage of Early Precision QT at ICON's Clinical Research Unit and access:
Fast, definitive results. Bring your product to market faster with proven high precision ECG collection, 10x the ECG data, higher quality cardiac beats, and low data variability.
Cost-effective assessment. Marginal costs for including EQPT in a First in Man SAD/MAD study is $15k for ECG capture and $150k for full QT analysis vs $2M - $5M cost of a traditional TQT study
De-risked development. De-risk your compound relative to QT liability during Phase I. EPQT's earlier cardiac safety assessment empowers confident and cost-effective drug development.
Better pipeline prioritization. EPQT delivers definitive QT liability information during the early stages of the development process, enabling you to make more informed decisions.